Wie hoch ist der Preis für Nabriva Therapeutics plc (NBRV)

Preis für Nabriva Therapeutics plc (NBRV) ist $0.63

Wie hoch ist die Marktkapitalisierung für Nabriva Therapeutics plc (NBRV)

Marktkapitalisierung für Nabriva Therapeutics plc (NBRV) ist $284.20K

Nabriva Therapeutics plc (NBRV) KBV

Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.

Jahr	P/B-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/B-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.2613	-	US
Argenx SE ARGX.US	6.3483	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.634	-	BE

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land